https://www.nasdaq.com/press-release/angion-provides-corporate-update-and-announces-participation-in-upcoming-investor
https://www.nasdaq.com/press-release/vifor-pharma-and-angion-report-topline-results-from-phase-ii-guard-trial-of-ang-3777
https://www.nasdaq.com/press-release/angion-and-vifor-pharma-report-topline-results-from-phase-2-guard-trial-of-ang-3777
https://www.nasdaq.com/press-release/angion-provides-corporate-update-and-reports-third-quarter-2021-financial-results
https://www.nasdaq.com/press-release/angion-presents-multiple-posters-on-ang-3070-at-kidney-week-2021-including
https://www.nasdaq.com/press-release/angion-to-participate-in-upcoming-investment-conference-2021-11-02
https://www.nasdaq.com/press-release/vifor-pharma-and-angion-report-topline-results-from-phase-iii-registration-trial-of
https://www.nasdaq.com/press-release/angion-and-vifor-pharma-report-topline-results-from-phase-3-trial-of-ang-3777-in
https://www.nasdaq.com/press-release/angion-to-present-multiple-posters-at-kidney-week-2021-2021-10-18
https://www.nasdaq.com/press-release/angion-hosting-research-development-day-on-ang-3070-for-the-treatment-of-lung-and
https://www.nasdaq.com/press-release/angion-to-participate-in-upcoming-september-investment-conferences-2021-09-02
https://www.nasdaq.com/press-release/angion-provides-corporate-update-and-reports-second-quarter-2021-financial-results
https://www.nasdaq.com/press-release/angion-reports-positive-results-from-phase-1-healthy-volunteer-study-for-ang-3070-and
https://www.nasdaq.com/press-release/angion-announces-results-from-the-phase-2-ali-201-study-in-patients-with-covid-19
https://www.nasdaq.com/press-release/angion-provides-corporate-update-and-reports-first-quarter-2021-financial-results
https://www.nasdaq.com/press-release/vifor-pharma-and-angion-announce-completion-of-enrollment-in-phase-ii-study-of-ang
https://www.nasdaq.com/press-release/angion-and-vifor-pharma-announce-completion-of-enrollment-in-phase-2-study-of-ang
https://www.nasdaq.com/press-release/angion-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2020
https://www.nasdaq.com/press-release/angion-completes-enrollment-in-phase-2-study-of-ang-3777-for-acute-lung-injury-in
https://www.nasdaq.com/press-release/angion-announces-partial-waiver-of-certain-lock-up-restrictions-2021-03-18
